Company profile for Acorda Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurologic...
Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
420 Saw Mill River Road, Ardsley, NY United States 10502
Telephone
Telephone
1-800-367-5109
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/pharma/germanys-merz-plots-us-workforce-increase-ceo-eyes-further-acquisitions-following-185m-asset

FIERCE PHARMA
12 Jul 2024

https://www.pharmaceutical-technology.com/news/merz-wins-185m-bid-for-bankrupt-acorda-assets-and-increases-us-workforce-by-50/

PHARMACEUTICAL-TECHNOLOGY
11 Jul 2024

https://www.businesswire.com/news/home/20240710459851/en

BUSINESSWIRE
10 Jul 2024

https://www.fiercepharma.com/marketing/ahead-bankruptcy-sale-acorda-fights-new-inbrija-tv-spot

Andrea Park FIERCE PHARMA
04 Jun 2024

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-supernus-drug-device-combination-parkinsons-disease-2024-04-08/

REUTERS
09 Apr 2024
Acorda files for bankruptcy, inks $185M asset deal to Merz
Acorda files for bankruptcy, inks $185M asset deal to Merz

03 Apr 2024

// Zoey Becker FIERCE PHARMA

https://www.fiercepharma.com/pharma/acorda-inks-185m-asset-deal-merz-therapeutics-files-bankruptcy-after-years-disappointing

Zoey Becker FIERCE PHARMA
03 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty